INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR PHARMACEUTICAL UTILIZATION AND FINANCIAL IMPACT IN A VALUE-BASED CARE PROGRAM.

Cyrus Daruwalla,Julia Andrieni,Enshuo Hsu,Sidra Uzair,Charles C Wykoff,Andrew G Lee

Retina (Philadelphia, Pa.)（2023）

引用 0|浏览3

暂无评分

摘要

Despite the lower price which may correlate with value-based care, bevacizumab was the least used anti-VEGF treatment. COVID-19 correlated with a larger decrease in the utilization of all three anti-VEGF drugs.

查看译文

关键词

accountable care organization,aflibercept,anti-vascular endothelial growth factor,bevacizumab,COVID-19,ranibizumab,value-based care

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要